» Articles » PMID: 14748809

In Defence of Polypharmacy

Overview
Specialty Pharmacology
Date 2004 Jan 30
PMID 14748809
Citations 20
Authors
Affiliations
Soon will be listed here.
Citing Articles

Polypharmacy trajectories among older women with and without dementia: A longitudinal cohort study.

Thapaliya K, Harris M, Byles J Explor Res Clin Soc Pharm. 2022; 3:100053.

PMID: 35480610 PMC: 9031090. DOI: 10.1016/j.rcsop.2021.100053.


The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.

Rahman S, Singh K, Dhingra S, Charan J, Sharma P, Islam S Ther Clin Risk Manag. 2020; 16:1007-1022.

PMID: 33116550 PMC: 7586020. DOI: 10.2147/TCRM.S272908.


Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review.

Taghy N, Cambon L, Cohen J, Dussart C Ther Clin Risk Manag. 2020; 16:57-73.

PMID: 32103967 PMC: 7023902. DOI: 10.2147/TCRM.S214187.


Important Design Features of Personal Health Records to Improve Medication Adherence for Patients with Long-Term Conditions: Protocol for a Systematic Literature Review.

Andrikopoulou E, Scott P, Herrera H JMIR Res Protoc. 2018; 7(6):e159.

PMID: 29954729 PMC: 6116916. DOI: 10.2196/resprot.9778.


Beliefs about prescribed medication among older patients with polypharmacy: a mixed methods study in primary care.

Clyne B, Cooper J, Boland F, Hughes C, Fahey T, Smith S Br J Gen Pract. 2017; 67(660):e507-e518.

PMID: 28533200 PMC: 5540192. DOI: 10.3399/bjgp17X691073.


References
1.
Movig K, Leufkens H, Lenderink A, van den Akker V, Hodiamont P, Goldschmidt H . Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol. 2002; 53(4):363-9. PMC: 1874265. DOI: 10.1046/j.1365-2125.2002.01550.x. View

2.
Heeley E, Wilton L, Shakir S . Automated signal generation in prescription-event monitoring. Drug Saf. 2002; 25(6):423-32. DOI: 10.2165/00002018-200225060-00006. View

3.
Standl E, Fuchtenbusch M . The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. Diabetologia. 2003; 46 Suppl 1:M30-6. DOI: 10.1007/s00125-002-0934-2. View

4.
Wald N, Law M . A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404):1419. PMC: 162259. DOI: 10.1136/bmj.326.7404.1419. View